News
CMXHF
71.50
NaN%
--
Citi Sticks to Its Hold Rating for CSL (CMXHF)
TipRanks · 9h ago
Analysts Offer Insights on Healthcare Companies: CSL (OtherCMXHF) and Apogee Therapeutics (APGE)
TipRanks · 2d ago
Jarden downgrades CSL (CMXHF) to a Hold
TipRanks · 2d ago
Canaccord Genuity downgrades CSL (CMXHF) to a Hold
TipRanks · 2d ago
CSL Seqirus signs long-term PAHO pandemic influenza vaccine supply agreement
PUBT · 2d ago
PAHO SIGNS AGREEMENT TO RESERVE PANDEMIC INFLUENZA VACCINE SUPPLY FOR LATIN AMERICA AND THE CARIBBEAN
Reuters · 2d ago
PAHO: AGREEMENT WITH CSL SEQIRUS AIMED AT SECURING RESERVED SHARE OF PANDEMIC INFLUENZA VACCINES PRODUCTION FOR COUNTRIES IN LATIN AMERICA, CARIBBEAN
Reuters · 2d ago
Analysts Conflicted on These Healthcare Names: CSL (OtherCMXHF) and Tilray (TLRY)
TipRanks · 2d ago
Analysts Have Conflicting Sentiments on These Healthcare Companies: CSL (OtherCMXHF) and Tandem Diabetes Care (TNDM)
TipRanks · 3d ago
Ord Minnett Keeps Their Hold Rating on CSL (CMXHF)
TipRanks · 3d ago
CSL (CMXHF) Receives a Buy from Morgans
TipRanks · 3d ago
Morgan Stanley Reaffirms Their Buy Rating on CSL (CMXHF)
TipRanks · 3d ago
BUZZ-CSL slips 6% as Citi slashes target price, Morningstar urges firm to hire new CEO
Reuters · 3d ago
CSL (CMXHF) Receives a Hold from Bell Potter
TipRanks · 3d ago
CSL downgraded to Neutral from Buy at Citi
TipRanks · 3d ago
Analysts Have Conflicting Sentiments on These Healthcare Companies: CSL (OtherCMXHF), Roche Holding AG (OtherRHHVF) and Pfizer (PFE)
TipRanks · 4d ago
Macquarie Sticks to Their Hold Rating for CSL (CMXHF)
TipRanks · 4d ago
BRIEF-CSL Expects FY26 Revenue $15.2 Bln, NPATA $3.1 Bln At Constant Currency
Reuters · 4d ago
CSL Cuts FY26 Guidance After Interim CEO’s 90-Day Review
TipRanks · 4d ago
CSL (CMXHF) Receives a Buy from UBS
TipRanks · 05/08 00:39
More
Webull provides a variety of real-time CMXHF stock news. You can receive the latest news about CSL through multiple platforms. This information may help you make smarter investment decisions.
About CMXHF
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with approximately 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China (including Hong Kong). Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam, and others.